Orient Cement Regulatory Approval

Earnings Call

Orient Cement Investor Presentation: Key Takeaways

Ambuja Cements consolidated Q2FY27 (filed under Orient cover letter): revenue flat at ₹9,197 Cr, EBITDA down 28% to ₹1,271 Cr, margin 13.8%, hit by ₹376 Cr geopolitical cost shock. Debt-free.

Share Pledge

Orient Cement Share Pledge

Deutsche Bank reported an encumbrance over 72.66% of Orient Cement shares, extended to a new Endeavour facility. No shares changed hands and no value is stated.

Financial Results

Orient Cement Q2 FY27 Results: Net Profit ₹32 Cr, Down 34.7% YoY

Orient Cement Ltd reported revenue from operations of ₹565 Cr (-12.1% YoY) and net profit of ₹32 Cr (-34.7% YoY) for Q2 FY27.

Key figure

Net profit ₹32 Cr · -34.7% YoY

Other Announcement

Orient Cement Other Announcement

Orient Cement Ltd has filed its shareholding pattern for the quarter ended September 30, 2026, as per regulatory requirements.

Board Meeting Date

Orient Cement Board Meeting Date

Orient Cement Limited has scheduled a board meeting for October 22, 2026, to approve unaudited financial results for the quarter and half-year ended September 30, 2026.

Acquisition

Orient Cement Acquisition

Orient Cement's equity shareholders approved the Scheme of Amalgamation with Ambuja Cements Limited at the NCLT-convened meeting held on September 28, 2026.

Regulatory ApprovalShalby Ltd SHALBYAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Shalby Regulatory Approval

Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.

Regulatory ApprovalElantas Beck India Ltd ELANTASAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Elantas Beck India Regulatory Approval

Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.

Regulatory ApprovalKalyani Cast-Tech Ltd 544023Alfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Kalyani Cast-Tech Regulatory Approval

Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.

Regulatory ApprovalMukka Proteins Ltd MUKKAAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Mukka Proteins Regulatory Approval

Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.

Execution

October 1, 2026 to December 31, 2027

Regulatory ApprovalCanara Bank CANBKAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Canara Bank Regulatory Approval

Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.

Value

₹1,500 Cr

Regulatory ApprovalAlembic Pharmaceuticals Ltd APLLTDAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.